verezdoВестник репродуктивного здоровьяBulletin of Reproductive Health2075-65692310-421XEndocrinology Research Centre (Moscow)10.14341/brh12804verezdo-12804Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESКонсенсусное заключение по итогам междисциплинарного экспертного совета с международным участием по вопросам персонализированного назначения заместительной гормональной терапии/менопаузальной гормональной терапии у женщин в различные возрастные периодыConsensus statement on the results of the interdisciplinary expert council meeting with international participation on personalized prescription of hormone replacement therapy/menopausal hormone therapy in women at different age periodhttps://orcid.org/0000-0002-2364-6838БаланВ. Е.BalanV. E.

Балан Вера Ефимовна , д.м.н., профессор

Vera E. Balan, MD, PhD, Professor

balanmed@gmail.comhttps://orcid.org/0000-0003-2864-066XЮреневаС. Ю.YurenevaS. V.

Юренева Светлана Владимировна, д.м.н., профессор

Svetlana V. Yureneva, MD, PhD, Professor

syureneva@gmail.comhttps://orcid.org/0000-0002-6551-4147ЯрмолинскаяМ. И.YarmolinskayaM. I.

Ярмолинская Мария Игоревна , д.м.н., профессор

Maria I. Yarmolinskaya, MD, PhD, Professor

m.yarmolinskaya@gmail.comhttps://orcid.org/0000-0001-8425-0020АндрееваЕ. Н.AndreevaE. N.

Андреева Елена Николаевна , д.м.н., профессор

117036, Москва, ул. Дм. Ульянова, д. 11

Elena N. Andreeva, MD, PhD, Professor

11 Dm. Ulyanova street, 117036 Moscow

endogin@mail.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна , член-корреспондент РАН, д.м.н., профессор

Oksana M. Drapkina, MD, PhD, Professor

drapkina@bk.ruhttps://orcid.org/0000-0002-9813-2823БарановИ. И.BaranovI. I.

Баранов Игорь Иванович , д.м.н., профессор

Igor I. Baranov, MD, Dr. Sc. (Med.)]

I_baranov@oparina4.ruhttps://orcid.org/0000-0001-6481-6277ХиршбергА. Л.HirschbergA. L.

Хиршберг Анжелика Линден , д.м.н., профессор, академик

Angelica Lindén Hirschberg, MD, PhD, Professor, Academician

angelica.hirschberg.linden@ki.sehttps://orcid.org/0000-0001-8046-0303КаноА.CanoA.

Кано Антонио , д.м.н., профессор

Cano Antonio, MD, PhD, Professor

Antonio.cano@uv.eshttps://orcid.org/0000-0003-1002-1895БернсС. А.BernsS. A.

Бернс Светлана Александровна, д.м.н., профессор

Svetlana A.Berns, MD, PhD, Professor

sberns@gnmicpm.ruhttps://orcid.org/0000-0003-2816-1183ЯвеловИ. С.YavelovI. S.

 Явелов Игорь Семенович , д.м.н., профессор 

Igor S. Yavelov, MD, PhD, Professor

yavelov@yahoo.comhttps://orcid.org/0000-0002-7142-3719СергеевА. В.SergeevA. V.

Сергеев Алексей Владимирович , д.м.н., профессор

Alexey V.Sergeev, Doctor of Sciences, Professor

sergeev.neuro@gmail.comhttps://orcid.org/0000-0002-8249-6075ДораС. В.DoraS. V.

Дора Светлана Владимировна, д.м.н., профессор

Svetlana V. Dora, PhD, Doctor of Sciences

doras2001@mail.ruhttps://orcid.org/0000-0003-3811-5156ДженинаО. В.DzheninaO. V.

Дженина Ольга Вадимовна , к.м.н. 

Olga V. Dzhenina, MD, PhD

dzhenina@rambler.ruhttps://orcid.org/0000-0002-1388-5827АкиньшинаС. В.AkinshinaS. V.

Акиньшина Светлана Владимировна , к.м.н.

Svetlana V.Akinshina, MD, PhD

svetlana_akin@mail.ruhttps://orcid.org/0000-0003-1955-1032СкибаЯ. Б.SkibaYa. B.

Скиба Ярослав Богданович , к.м.н.

Yaroslav B. Skiba, MD, PhD

yaver-99@mail.ruhttps://orcid.org/0000-0001-6381-2450ТалибовО. Б.TalibovO. B.

Талибов Олег Букарович , к.м.н., доцент 

Oleg B.Talibov, MD,PhD, Docent

oleg.talibov@gmail.comГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии»РоссияMoscow Regional Research Institute of Obstetrics and GynecologyRussian FederationФГБУ «НМИЦ АГП им. В.И. Кулакова» Минздрава РоссииРоссияNational Medical Research Center of Obstetrics, Gynecology and PerinatologyRussian FederationФГБНУ «НИИ АГиР им. Д.О. Отта»РоссияResearch Institute of Obstetrics, Gynecology, and Reproductology named after D.O. OttRussian FederationГНЦ РФ ФГБУ «Национальный медицинский исследовательский центр эндокринологии им. академика И.И. Дедова» Минздрава России; ФГБОУ ВО «Российский университет медицины» Минздрава РоссииРоссияEndocrinology Research Centre; Russian Ministry of HealthRussian FederationФГБУ «НМИЦ ТПМ» Минздрава РоссииRussian FederationNational Medical Research Center for Therapy and Preventive MedicineRussian FederationКаролинский институтШвецияKarolinska InstitutetSwedenСевильский университетИспанияUniversity of SevilleSpainФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава РоссииРоссияPavlov UniversityRussian FederationООО «Первый флебологический центр»РоссияFirst Phlebological Centre» LLCRussian FederationСеченовский УниверситетРоссияSechenov UniversityRussian FederationНИИ детской онкологии, гематологии и трансплантологии им. Р.М. ГорбачевойРоссияRaisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and TransplantationRussian FederationФГБОУ ВО «Российский университет медицины» Минздрава РоссииРоссияRussian Ministry of HealthRussian Federation202603082026521026Copyright © Балан В.Е., Юренева С.Ю., Ярмолинская М.И., Андреева Е.Н., Драпкина О.М., Баранов И.И., Хиршберг А.Л., Кано А., Бернс С.А., Явелов И.С., Сергеев А.В., Дора С.В., Дженина О.В., Акиньшина С.В., Скиба Я.Б., Талибов О.Б., 20262026Балан В.Е., Юренева С.Ю., Ярмолинская М.И., Андреева Е.Н., Драпкина О.М., Баранов И.И., Хиршберг А.Л., Кано А., Бернс С.А., Явелов И.С., Сергеев А.В., Дора С.В., Дженина О.В., Акиньшина С.В., Скиба Я.Б., Талибов О.Б.Balan V.E., Yureneva S.V., Yarmolinskaya M.I., Andreeva E.N., Drapkina O.M., Baranov I.I., Hirschberg A.L., Cano A., Berns S.A., Yavelov I.S., Sergeev A.V., Dora S.V., Dzhenina O.V., Akinshina S.V., Skiba Y.B., Talibov O.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vrz-endojournals.ru/jour/article/view/12804

Значительное снижение уровня эстрогенов, обусловленное наступлением менопаузы, является причиной развития клинически значимых симптомов климактерического синдрома, существенно ухудшающих качество жизни, а также относится к факторам, повышающим долгосрочные кардиометаболические риски. Согласно действующим российским клиническим рекомендациям, менопаузальная гормональная терапия (МГТ) рассматривается в качестве наиболее эффективного метода коррекции климактерических расстройств.

Для проработки актуальных вопросов ведения пациенток в периодах перии постменопаузы и особенностей назначения МГТ в различных клинических ситуациях в последнем квартале 2025 г. был созван Междисциплинарный экспертный совет, основной задачей которого стала оптимизация научно обоснованных алгоритмов ведения пациенток с климактерическими/постовариоэктомическими синдромами. По итогам работы специалистами национального и международного уровня, представляющими различные области медицины, был утвержден консенсусный документ, регламентирующий принципы назначения заместительной/менопаузальной гормональной терапии женщинам с сопутствующей соматической патологией.

A significant decrease in estrogen levels due to the onset of menopause is the cause of the development of clinically significant symptoms of climacteric syndrome, which significantly impair the quality of life, and also refers to factors that increase long-term cardiometabolic risks. According to the current Russian clinical recommendations, menopausal hormone therapy (MHT) is considered as the most effective method for the correction of climacteric disorders.

An Interdisciplinary Expert Council was convened in the last quarter of 2025 to study the topical issues of managing patients in the peri-and postmenopausal periods and the specifics of prescribing MHT in various clinical situations, the main task of which was to optimize scientifically based algorithms for the management of patients with climacteric/postovariectomy syndromes. Based on the results of work by national and international specialists representing various fields of medicine, a consensus document was approved regulating the principles for prescribing HRT/MHT to women with concomitant somatic pathology.

менопаузальная гормональная терапияменопаузаклимактерический синдромсердечно-сосудистые заболеванияметаболические заболеваниямеждисциплинарный советmenopausal hormonal therapymenopauseclimacteric syndromecardiovascular diseasesmetabolic diseasesinterdisciplinary expert councilReferencesDelanerolle G., Phiri P., Elneil S., Talaulikar V., Eleje G.U., Kareem R. et al.; MARIE collaborative. Menopause: a global health and wellbeing issue that needs urgent attention. Lancet Glob. Health. 2025; 13(2): e196-e198. https://dx.doi.org/10.1016/S2214-109X(24)00528-XDelanerolle G, Phiri P, Elneil S, Talaulikar V, Eleje GU, Kareem R, et al.; MARIE collaborative. Menopause: a global health and wellbeing issue that needs urgent attention. Lancet Glob. Health. 2025;13(2):e196-e198. doi: https://dx.doi.org/10.1016/S2214-109X(24)00528-XWНО. Menopause. 2024. Available at: www.who.int/news-room/fact-sheets/detail/menopauseWНО. Menopause. 2024. Available at: www.who.int/news-room/fact-sheets/detail/menopauseBurki T. Rossella Nappi: taking the stigma out of menopause. Lancet Diabetes Endocrinol. 2023; 11(4): 232. https://dx.doi.org/10.1016/S2213-8587(23)00057-8Burki T. Rossella Nappi: taking the stigma out of menopause. Lancet Diabetes Endocrinol. 2023;11(4):232. doi: https://dx.doi.org/10.1016/S2213-8587(23)00057-8Thavabalan K., Ovenell A., Pierce P., Sutaria A., Parkhouse A., Baydemir N. et al. Barriers to the safe discussion of the experience and management of menopausal symptoms: A systematic literature review. Maturitas. 2025; 201: 108683. https://dx.doi.org/10.1016/j.maturitas.2025.108683Thavabalan K, Ovenell A, Pierce P, Sutaria A, Parkhouse A, Baydemir N, et al. Barriers to the safe discussion of the experience and management of menopausal symptoms: A systematic literature review. Maturitas. 2025;201:108683. doi: https://dx.doi.org/10.1016/j.maturitas.2025.108683Сметник А.А., Иванов И.А., Ермакова Е.И., Табеева Г.И. Особенности использования менопаузальной гормональной терапии в России: результаты масштабного опроса женщин в пери- и постменопаузе. Акушерство и гинекология. 2025; 8: 196-208.Smetnik A.A., Ivanov I.A., Ermakova E.I., Tabeeva G.I. Characteristics of menopausal hormone therapy use in Russia: results of a large-scale survey of peri- and postmenopausal women. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (8): 196-208 (in Russian). doi: https://dx.doi.org/10.18565/aig.2025.200Panay N., Fenton A., Hamoda H., Hillard T., Islam R., Pedder H. et al.; (IMS Publication Steering Committee) and The IMS Recommendations Writing Group; IMS Recommendations Writing Group; With valuable support provided by. International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. Climacteric. 2025; 28(6): 634-656. https://dx.doi.org/10.1080/13697137.2025.2585487Panay N, Fenton A, Hamoda H, Hillard T, Islam R, Pedder H, et al.; (IMS Publication Steering Committee) and The IMS Recommendations Writing Group; IMS Recommendations Writing Group; With valuable support provided by. International Menopause Society (IMS) recommendations and key messages on women’s midlife health and menopause. Climacteric. 2025;28(6):634-656. doi: https://dx.doi.org/10.1080/13697137.2025.2585487Johansson T., Karlsson T., Bliuc D., Schmitz D., Ek W.E., Skalkidou A. et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024; 387: e078784. https://dx.doi.org/10.1136/bmj-2023-078784Johansson T, Karlsson T, Bliuc D, Schmitz D, Ek WE, Skalkidou A, et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024;387:e078784. doi: https://dx.doi.org/10.1136/bmj-2023-078784Xia W., Khalil R.A. Hormone replacement therapy and cardiovascular health in postmenopausal women. Int. J. Mol. Sci. 2025; 26(11): 5078. https://dx.doi.org/10.3390/ijms26115078Xia W, Khalil RA. Hormone replacement therapy and cardiovascular health in postmenopausal women. Int. J. Mol. Sci. 2025;26(11):5078. doi: https://dx.doi.org/10.3390/ijms26115078Kim Y., Cho M.K., Chung Y.J., Hong S.H., Hwang K.R., Jeon G.H. et al.; Publication Committee on Clinical Guidelines of the Korean Society of Menopause. The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause. J. Menopausal Med. 2025; 31(2): 53-84. https://dx.doi.org/10.6118/jmm.25103Kim Y, Cho MK, Chung YJ, Hong SH, Hwang KR, Jeon GH, et al.; Publication Committee on Clinical Guidelines of the Korean Society of Menopause. The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause. J. Menopausal Med. 2025;31(2):53-84. doi: https://dx.doi.org/10.6118/jmm.25103“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022; 29(7): 767-94. https://dx.doi.org/10.1097/GME.0000000000002028“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-94. doi: https://dx.doi.org/10.1097/GME.0000000000002028European Menopause and Andropause Society (EMAS). EMAS statement on the FDA decision to remove “Black Box” warnings from Menopausal Hormone Therapy (MHT). Available at: https://www.linkedin.com/pulse/emas-statement-fda-decision-remove-cpmgfEuropean Menopause and Andropause Society (EMAS). EMAS statement on the FDA decision to remove “Black Box” warnings from Menopausal Hormone Therapy (MHT). Available at: https://www.linkedin.com/pulse/emas-statement-fda-decision-remove-cpmgfhttps://edition.cnn.com/2025/10/02/health/menopause-hrt-warning-change-makaryhttps://edition.cnn.com/2025/10/02/health/menopause-hrt-warning-change-makaryESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024; 27(6): 510-20. https://dx.doi.org/10.1080/13697137.2024.2423213ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N, Anderson RA, Bennie A, Cedars M, Davies M, Ee C, et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024;27(6):510-20. doi: https://dx.doi.org/10.1080/13697137.2024.2423213Panay N., Anderson R.A., Nappi R.E., Vincent A.J., Vujovic S., Webber L. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020; 23(5): 426-46. https://dx.doi.org/10.1080/13697137.2020.1804547Panay N, Anderson RA, Nappi RE, Vincent AJ, Vujovic S, Webber L, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426-46. doi: https://dx.doi.org/10.1080/13697137.2020.1804547Li X.T., Li P.Y., Liu Y., Yang H.S., He L.Y., Fang Y.G. et al. Health-related quality-of-life among patients with premature ovarian insufficiency: a systematic review and meta-analysis. Qual Life Res. 2020; 29(1):19-36. https://dx.doi.org/10.1007/s11136-019-02326-2Li XT, Li PY, Liu Y, Yang HS, He LY, Fang YG, et al. Health-related quality-of-life among patients with premature ovarian insufficiency: a systematic review and meta-analysis. Qual Life Res. 2020;29(1):19-36. doi: https://dx.doi.org/10.1007/s11136-019-02326-2Honigberg M.C., Zekavat S.M., Aragam K., Finneran P., Klarin D., Bhatt D.L. et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019; 322(24): 2411-21. https://dx.doi.org/10.1001/jama.2019.19191Honigberg MC, Zekavat SM, Aragam K, Finneran P, Klarin D, Bhatt DL, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411-21. doi: https://dx.doi.org/10.1001/jama.2019.19191Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023; 5: 50-8.Averkova V.G., Yureneva S.V. Quality of life in patients with premature ovarian insufficiency treated with hormone replacement therapy. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (5): 50-58 (in Russian). doi: https://dx.doi.org/10.18565/aig.2023.16https://www.who.int/ru/initiatives/decade-of-healthy-ageinghttps://www.who.int/ru/initiatives/decade-of-healthy-ageingMansour D., Barber K., Chalk G., Noble N., Digpal A.A.S., Talaulikar V. et al. The evolving perspective of menopause management in the United Kingdom. Womens Health (Lond). 2024; 20: 17455057241288641. )]. https://dx.doi.org/10.1177/17455057241288641Mansour D, Barber K, Chalk G, Noble N, Digpal AAS, Talaulikar V, et al. The evolving perspective of menopause management in the United Kingdom. Womens Health (Lond). 2024;20:17455057241288641)]. doi: https://dx.doi.org/10.1177/17455057241288641Наделяева Я.Г., Данусевич И.Н. Особенности менопаузы, осведомленность и качество жизни женщин, проживающих в городской и сельской местности. Доктор.Ру. 2025; 24(1): 81-7.Nadeliaeva Ia.G., Danusevich I.N. Specifics of menopause, awareness and quality of life of women living in urban and rural areas. Doctor.Ru. 2025;24(1):81–87. doi: https://dx.doi.org/10.31550/1727-2378-2025-24-1-81-87Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2025.Ministry of Health of the Russian Federation. Clinical recommendations “Menopause and female climacteric conditions”. Version of 2025 year.El Khoudary S.R., Aggarwal B., Beckie T.M., Hodis H.N., Johnson A.E., Langer R.D. et al.; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation. 2020; 142(25): e506-e532. https://dx.doi.org/10.1161/CIR.0000000000000912El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al.; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation. 2020;142(25):e506-e532. doi: https://dx.doi.org/10.1161/CIR.0000000000000912Stuenkel C.A. Reproductive milestones across the lifespan and cardiovascular disease risk in women. Climacteric. 2024; 27(1): 5-15. https://dx.doi.org/10.1080/13697137.2023.2259793Stuenkel CA. Reproductive milestones across the lifespan and cardiovascular disease risk in women. Climacteric. 2024;27(1):5-15. doi: https://dx.doi.org/10.1080/13697137.2023.2259793Thurston R.C., Aslanidou Vlachos H.E., Derby C.A., Jackson E.A., Brooks M.M., Matthews K.A. et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J. Am. Heart Assoc. 2021; 10(3): e017416. https://dx.doi.org/10.1161/JAHA.120.017416Thurston RC, Aslanidou Vlachos HE, Derby CA, Jackson EA, Brooks MM, Matthews KA, et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J. Am. Heart Assoc. 2021;10(3):e017416. doi: https://dx.doi.org/10.1161/JAHA.120.017416Boardman H.M., Hartley L., Eisinga A., Main C., Roqué i Figuls M., Bonfill Cosp X. et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 2015; 2015(3): CD002229. https://dx.doi.org/10.1002/14651858.CD002229.pub4Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 2015;2015(3): CD002229. doi: https://dx.doi.org/10.1002/14651858.CD002229.pub4Schierbeck L.L., Rejnmark L., Tofteng C.L., Stilgren L., Eiken P., Mosekilde L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012; 345: e6409. https://dx.doi.org/10.1136/bmj.e6409Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. doi: https://dx.doi.org/10.1136/bmj.e6409Johansson T., Karlsson T., Bliuc D., Schmitz D., Ek W.E., Skalkidou A. et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024; 387: e078784. https://dx.doi.org/10.1136/bmj-2023-078784Johansson T, Karlsson T, Bliuc D, Schmitz D, Ek WE, Skalkidou A, et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024;387:e078784. doi: https://dx.doi.org/10.1136/bmj-2023-078784Oliver-Williams C., Glisic M., Shahzad S., Brown E., Pellegrino Baena C., Chadni M. et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum. Reprod. Update. 2019; 25(2): 257-71. https://dx.doi.org/10.1093/humupd/dmy039Oliver-Williams C, Glisic M, Shahzad S, Brown E, Pellegrino Baena C, Chadni M, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum. Reprod. Update. 2019;25(2):257-71. doi: https://dx.doi.org/10.1093/humupd/dmy039Kalenga C.Z., Metcalfe A., Robert M., Nerenberg K.A., MacRae J.M., Ahmed S.B. Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women: a prospective population-based study. Hypertension. 2023; 80(7):1463-73. https://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19938Kalenga CZ, Metcalfe A, Robert M, Nerenberg KA, MacRae JM, Ahmed SB. Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women: a prospective population-based study. Hypertension. 2023;80(7):1463-73. doi: https://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19938Cho L., Kaunitz A.M., Faubion S.S., Hayes S.N., Lau E.S., Pristera N. et al.; ACC CVD in Women Committee. Rethinking menopausal hormone therapy: For whom, what, when, and how long? Circulation. 2023; 147(7): 597-610. https://dx.doi.org/10.1161/CIRCULATIONAHA.122.061559Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N, et al.; ACC CVD in Women Committee. Rethinking menopausal hormone therapy: For whom, what, when, and how long? Circulation. 2023;147(7):597-610. doi: https://dx.doi.org/10.1161/CIRCULATIONAHA.122.061559Mueck A.O., Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2005; 3(1): 45-54. https://dx.doi.org/10.2174/1568016052773270Mueck AO, Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2005;3(1):45-54. doi: https://dx.doi.org/10.2174/1568016052773270Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И., Арутюнов Г.П., Сучков И.А. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России. Акушерство и гинекология. 2023; 11: 211-32.Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И., Арутюнов Г.П., Сучков И.А. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России. // Акушерство и гинекология. — 2023. — №11. — С. 211-32Straczek C., Oger E., Yon de Jonage-Canonico M.B., Plu-Bureau G., Conard J., Meyer G. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112(22): 3495-500. https://dx.doi.org/10.1161/CIRCULATIONAHA.105.565556Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005;112(22):3495-500. doi: https://dx.doi.org/10.1161/CIRCULATIONAHA.105.565556Olié V., Canonico M., Scarabin P.Y. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr. Opin. Hematol. 2010; 17(5): 457-63. https://dx.doi.org/10.1097/MOH.0b013e32833c07bcOlié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr. Opin. Hematol. 2010;17(5):457-63. doi: https://dx.doi.org/10.1097/MOH.0b013e32833c07bcMohammed K., Abu Dabrh A.M., Benkhadra K., Al Nofal A., Carranza Leon B.G., Prokop L.J. et al. Oral vs Transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2015; 100(11): 4012-20. https://dx.doi.org/10.1210/jc.2015-2237Mohammed K, Abu Dabrh AM, Benkhadra K, Al Nofal A, Carranza Leon BG, Prokop LJ, et al. Oral vs Transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2015;100(11):4012-20. doi: https://dx.doi.org/10.1210/jc.2015-2237Зотова И.В., Затейщиков Д.А. Наследственная тромбофилия и венозные тромбоэмболические осложнения: правила тестирования в клинической практике. Российский кардиологический журнал. 2020; 25(3S): 4024.Zotova I.V., Zateyshchikov D.A. Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice. Russian Journal of Cardiology. 2020;25(3S):4024. doi: https://doi.org/10.15829/1560-4071-2020-4024]Dicks A.B., Moussallem E., Stanbro M., Walls J., Gandhi S., Gray B.H. A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism. J. Clin. Med. 2024; 13(2): 362. https://dx.doi.org/10.3390/jcm13020362Dicks AB, Moussallem E, Stanbro M, Walls J, Gandhi S, Gray BH. A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism. J. Clin. Med. 2024;13(2):362. doi: https://dx.doi.org/10.3390/jcm13020362Rovinski D., Ramos R.B., Fighera T.M., Casanova G.K., Spritzer P.M. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb. Res. 2018; 168: 83-95. https://dx.doi.org/10.1016/j.thromres.2018.06.014Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb. Res. 2018;168:83-95. doi: https://dx.doi.org/10.1016/j.thromres.2018.06.014Royal College of Obstetricians & Gynaecologists. Thromboembolic disease in pregnancy and the puerperium: Acute management. Green-top Guideline No. 37b. London: RCOG; 2015.Royal College of Obstetricians & Gynaecologists. Thromboembolic disease in pregnancy and the puerperium: Acute management. Green-top Guideline No. 37b. London: RCOG; 2015American College of Obstetricians and Gynecologists' Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 197: Inherited thrombophilias in pregnancy. Obstet. Gynecol. 2018; 132(1): e18-e34. https://dx.doi.org/10.1097/AOG.0000000000002703American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 197: Inherited thrombophilias in pregnancy. Obstet. Gynecol. 2018;132(1):e18-e34. doi: https://dx.doi.org/10.1097/AOG.0000000000002703Alnor A.B., Gils C., Vinholt P.J. Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis. Ann. Hematol. 2024; 103(10): 4285-94. https://dx.doi.org/10.1007/s00277-024-05926-2Alnor AB, Gils C, Vinholt PJ. Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis. Ann. Hematol. 2024;103(10):4285-94. doi: https://dx.doi.org/10.1007/s00277-024-05926-2Canonico M., Plu-Bureau G., Lowe G.D., Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008; 336(7655): 1227-31. https://dx.doi.org/10.1136/bmj.39555.441944.BECanonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227-31. doi: https://dx.doi.org/10.1136/bmj.39555.441944.BEFolsom A.R., Aleksic N., Wang L., Cushman M., Wu K.K., White R.H. Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. Arterioscler. Thromb. Vasc. Biol. 2002; 22(6): 1018-22. https://dx.doi.org/10.1161/01.atv.0000017470.08363.abFolsom AR, Aleksic N, Wang L, Cushman M, Wu KK, White RH. Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. Arterioscler. Thromb. Vasc. Biol. 2002;22(6):1018-22. doi: https://dx.doi.org/10.1161/01.atv.0000017470.08363.abACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet. Gynecol. 2013; 121(4): 887-90. https://dx.doi.org/10.1097/01.AOG.0000428645.90795.d9ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet. Gynecol. 2013;121(4):887-90. doi: https://dx.doi.org/10.1097/01.AOG.0000428645.90795.d9https://thebms.org.uk/wp-content/uploads/2025/04/09-BMS-TfC-NICE-Menopause-Menopause-identification-and-management-%E2%80%93-from-guideline-to-practice-MARCH2025-D.pdfhttps://thebms.org.uk/wp-content/uploads/2025/04/09-BMS-TfC-NICE-Menopause-Menopause-identification-and-management-%E2%80%93-from-guideline-to-practice-MARCH2025-D.pdfLumsden M.A., Dekkers O.M., Faubion S.S., Lindén Hirschberg A., Jayasena C.N., Lambrinoudaki I. et al. European society of endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur. J. Endocrinol. 2025; 193(4): G49-G81. https://dx.doi.org/10.1093/ejendo/lvaf206Lumsden MA, Dekkers OM, Faubion SS, Lindén Hirschberg A, Jayasena CN, Lambrinoudaki I, et al. European society of endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur. J. Endocrinol. 2025;193(4): G49-G81. doi: https://dx.doi.org/10.1093/ejendo/lvaf206Asmis L., Hellstern P. Thrombophilia testing - a systematic review. Clin. Lab. 2023; 69(4). https://dx.doi.org/10.7754/Clin.Lab.2022.220817Asmis L, Hellstern P. Thrombophilia testing - a systematic review. Clin. Lab. 2023;69(4). doi: https://dx.doi.org/10.7754/Clin.Lab.2022.220817Douketis J.D., Julian J.A., Kearon C., Anderson D.R., Crowther M.A., Bates S.M. et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J. Thromb. Haemost. 2005; 3(5): 943-8. https://dx.doi.org/10.1111/j.1538-7836.2005.01268.xDouketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J. Thromb. Haemost. 2005;3(5):943-8. doi: https://dx.doi.org/10.1111/j.1538-7836.2005.01268.xMiddeldorp S., Nieuwlaat R., Baumann Kreuziger L., Coppens M., Houghton D., James A.H. et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023; 7(22): 7101-38. https://dx.doi.org/10.1182/bloodadvances.2023010177Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, Coppens M, Houghton D, James AH, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023;7(22):7101-38. doi: https://dx.doi.org/10.1182/bloodadvances.2023010177Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Lévesque H. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7): 840-5. https://dx.doi.org/10.1161/CIRCULATIONAHA.106.642280Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-5. doi: https://dx.doi.org/10.1161/CIRCULATIONAHA.106.642280Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019; 364: k4810. https://dx.doi.org/10.1136/bmj.k4810Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364: k4810. doi: https://dx.doi.org/10.1136/bmj.k4810Hicks A., Robson D., Tellis B., Smith S., Dunkley S., Baber R. Safety of menopause hormone therapy in postmenopausal women at higher risk of venous thromboembolism: a systematic review. Climacteric. 2025; 28(5): 497-509. https://dx.doi.org/10.1080/13697137.2025.2503874Hicks A, Robson D, Tellis B, Smith S, Dunkley S, Baber R. Safety of menopause hormone therapy in postmenopausal women at higher risk of venous thromboembolism: a systematic review. Climacteric. 2025;28(5):497-509. doi: https://dx.doi.org/10.1080/13697137.2025.2503874Renoux C., Dell'Aniello S., Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J. Thromb. Haemost. 2010; 8(5): 979-86. https://dx.doi.org/10.1111/j.1538-7836.2010.03839.xRenoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J. Thromb. Haemost. 2010;8(5):979-86. doi: https://dx.doi.org/10.1111/j.1538-7836.2010.03839.xCanonico M., Fournier A., Carcaillon L., Olié V., Plu-Bureau G., Oger E. et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 2010; 30(2): 340-5. https://dx.doi.org/10.1161/ATVBAHA.109.196022Canonico M, Fournier A, Carcaillon L, Olié V, Plu-Bureau G, Oger E, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 2010;30(2):340-5. doi: https://dx.doi.org/10.1161/ATVBAHA.109.196022Sweetland S., Beral V., Balkwill A., Liu B., Benson V.S., Canonico M. et al.; Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J. Thromb. Haemost. 2012; 10(11): 2277-86. https://dx.doi.org/10.1111/j.1538-7836.2012.04919.xSweetland S, Beral V, Balkwill A, Liu B, Benson VS, et al.; Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J. Thromb. Haemost. 2012;10(11):2277-86. doi: https://dx.doi.org/10.1111/j.1538-7836.2012.04919.xManson J.E., Kaunitz A.M. Menopause management--getting clinical care back on track. N. Engl. J. Med. 2016; 374(9): 803-6. https://dx.doi.org/10.1056/NEJMp1514242Manson JE, Kaunitz AM. Menopause management--getting clinical care back on track. N. Engl. J. Med. 2016;374(9):803-6. doi: https://dx.doi.org/10.1056/NEJMp1514242Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric. 2018; 21(4): 346-54. https://dx.doi.org/10.1080/13697137.2018.1455657Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric. 2018;21(4):346-54. doi: https://dx.doi.org/10.1080/13697137.2018.1455657Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697137.2015.1129166Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50. doi: https://dx.doi.org/10.3109/13697137.2015.1129166Lambrinoudaki I., Armeni E., Goulis D., Bretz S., Ceausu I., Durmusoglu F. et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022; 163: 1-14. https://dx.doi.org/10.1016/j.maturitas.2022.04.008Lambrinoudaki I, Armeni E, Goulis D, Bretz S, Ceausu I, et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022;163:1-14. doi: https://dx.doi.org/10.1016/j.maturitas.2022.04.008Menopause: identification and management. London: National Institute for Health and Care Excellence (NICE); 2024 Nov 7.Menopause: identification and management. London: National Institute for Health and Care Excellence (NICE); 2024 Nov 7Genazzani A.R., Divakar H., Khadilkar S.S., Monteleone P., Evangelisti B., Galal A.F. et al. Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper. Int. J. Gynaecol. Obstet. 2024; 164(2): 516-30. https://dx.doi.org/10.1002/ijgo.15278Genazzani AR, Divakar H, Khadilkar SS, Monteleone P, Evangelisti B, et al. Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper. Int. J. Gynaecol. Obstet. 2024;164(2):516-30. doi: https://dx.doi.org/10.1002/ijgo.15278Ayzenberg I., Katsarava Z., Sborowski A., Chernysh M., Osipova V., Tabeeva G. et al.; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012; 32(5): 373-81. https://dx.doi.org/10.1177/0333102412438977Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, et al.; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012;32(5):373-81. doi: https://dx.doi.org/10.1177/0333102412438977Welch K.M., Brandes J.L., Berman N.E. Mismatch in how oestrogen modulates molecular and neuronal function may explain menstrual migraine. Neurol. Sci. 2006; 27 Suppl 2: S190-2. https://dx.doi.org/10.1007/s10072-006-0599-6Welch KM, Brandes JL, Berman NE. Mismatch in how oestrogen modulates molecular and neuronal function may explain menstrual migraine. Neurol. Sci. 2006;27 Suppl 2: S190-2. doi: https://dx.doi.org/10.1007/s10072-006-0599-6Ravi V., Osouli Meinagh S., Bavarsad Shahripour R. Reviewing migraine-associated pathophysiology and its impact on elevated stroke risk. Front. Neurol. 2024; 15: 1435208. https://dx.doi.org/10.3389/fneur.2024.1435208Ravi V, Osouli Meinagh S, Bavarsad Shahripour R. Reviewing migraine-associated pathophysiology and its impact on elevated stroke risk. Front. Neurol. 2024;15:1435208. doi: https://dx.doi.org/10.3389/fneur.2024.1435208Scottish Government Women’s Health and Heart Health Policy Teams with thanks to the numerous clinicians who helped and in collaboration with the medical advisory council of the British Menopause Society. Management of menopause for women with cardiovascular disease. Post Reprod. Health. 2024; 30(4): 280-4. https://dx.doi.org/10.1177/20533691241302040Scottish Government Women’s Health and Heart Health Policy Teams with thanks to the numerous clinicians who helped and in collaboration with the medical advisory council of the British Menopause Society. Management of menopause for women with cardiovascular disease. Post Reprod. Health. 2024;30(4):280-4. doi: https://dx.doi.org/10.1177/20533691241302040Ali N., Sohail R., Jaffer S.R., Siddique S., Kaya B., Atowoju I. et al. The role of estrogen therapy as a protective factor for Alzheimer's disease and dementia in postmenopausal women: a comprehensive review of the literature. Cureus. 2023; 15(8): e43053. https://dx.doi.org/10.7759/cureus.43053Ali N, Sohail R, Jaffer SR, Siddique S, Kaya B, Atowoju I, et al. The role of estrogen therapy as a protective factor for Alzheimer’s disease and dementia in postmenopausal women: a comprehensive review of the literature. Cureus. 2023;15(8):e43053. doi: https://dx.doi.org/10.7759/cureus.43053Maki P.M., Jaff N.G. Brain fog in menopause: A health-care professional's guide for decision-making and counseling on cognition. Climacteric. 2022; 25(6): 570-8. https://dx.doi.org/10.1080/13697137.2022.2122792Maki PM, Jaff NG. Brain fog in menopause: A health-care professional’s guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570-8. doi: https://dx.doi.org/10.1080/13697137.2022.2122792Garber J.R., Cobin R.H., Gharib H., Hennessey J.V., Klein I., Mechanick J.I. et al.; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012; 22(12): 1200-35. https://dx.doi.org/10.1089/thy.2012.0205Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, et al.; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200-35. doi: https://dx.doi.org/10.1089/thy.2012.0205Mintziori G., Veneti S., Poppe K., Goulis D.G., Armeni E., Erel C.T. et al. EMAS position statement: Thyroid disease and menopause. Maturitas. 2024; 185: 107991. https://dx.doi.org/10.1016/j.maturitas.2024.107991Mintziori G, Veneti S, Poppe K, Goulis DG, Armeni E, Erel CT, et al. EMAS position statement: Thyroid disease and menopause. Maturitas. 2024;185:107991. doi: https://dx.doi.org/10.1016/j.maturitas.2024.107991Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гипотиреоз. 2025.Ministry of Health of the Russian Federation. Clinical recommendations “Hypothyroidism”. Version of 2025 year.Kaminski J., Junior C.M., Pavesi H., Drobrzenski B., Amaral G.M.D. Effects of oral versus transdermal estradiol plus micronized progesterone on thyroid hormones, hepatic proteins, lipids, and quality of life in menopausal women with hypothyroidism: a clinical trial. Menopause. 2021; 28(9): 1044-52. https://dx.doi.org/10.1097/GME.0000000000001811Kaminski J, Junior CM, Pavesi H, Drobrzenski B, Amaral GMD. Effects of oral versus transdermal estradiol plus micronized progesterone on thyroid hormones, hepatic proteins, lipids, and quality of life in menopausal women with hypothyroidism: a clinical trial. Menopause. 2021;28(9):1044-52. doi: https://dx.doi.org/10.1097/GME.0000000000001811Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007; 92(2): 399-404. https://dx.doi.org/10.1210/jc.2006-0513Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92(2):399-404. doi: https://dx.doi.org/10.1210/jc.2006-0513International Diabetes Federation. Diabetes Atlas. 11th Edition – 2025. Available at: https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025-1.pdfInternational Diabetes Federation. Diabetes Atlas. 11th Edition – 2025. Available at: https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025-1.pdfДедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021; 24(3): 204-21.Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.А. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-221. (In Russ.). doi: https://doi.org/10.14341/DM12759Rossi R., Origliani G., Modena M.G. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care. 2004; 27(3): 645-9. https://dx.doi.org/10.2337/diacare.27.3.645Rossi R, Origliani G, Modena MG. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care. 2004;27(3):645-9. doi: https://dx.doi.org/10.2337/diacare.27.3.645Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes. Metab. 2006; 8(5): 538-54. https://dx.doi.org/10.1111/j.1463-1326.2005.00545.xSalpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes. Metab. 2006;8(5):538-54. doi: https://dx.doi.org/10.1111/j.1463-1326.2005.00545.xWHO. Obesity and overweight. 8 December 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweightWHO. Obesity and overweight. 8 December 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweightNCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024; 403(10431): 1027-50. https://dx.doi.org/10.1016/S0140-6736(23)02750-2NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027-50. doi: https://dx.doi.org/10.1016/S0140-6736(23)02750-2Giannini A. Menopause, hormone replacement therapy (HRT) and obesity. Curr. Res. Diab. Obes. J. 2018; 7(1): 555704. https://dx.doi.org/10.19080/CRDOJ.2018.07.555704Giannini A. Menopause, hormone replacement therapy (HRT) and obesity. Curr. Res. Diab. Obes. J. 2018;7(1):555704. doi: https://dx.doi.org/10.19080/CRDOJ.2018.07.555704Powell-Wiley T.M., Poirier P., Burke L.E., Després J.P., Gordon-Larsen P., Lavie C.J. et al.; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2021; 143(21): e984-e1010. https://dx.doi.org/10.1161/CIR.0000000000000973Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, et al.; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-e1010. doi: https://dx.doi.org/10.1161/CIR.0000000000000973Hotoleanu C. Association between obesity and venous thromboembolism. Med. Pharm. Rep. 2020; 93(2):162-8. https://dx.doi.org/10.15386/mpr-1372Hotoleanu C. Association between obesity and venous thromboembolism. Med. Pharm. Rep. 2020;93(2):162-8. doi: https://dx.doi.org/10.15386/mpr-1372Beaudart C., Zaaria M., Pasleau F., Reginster J.Y., Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One. 2017; 12(1): e0169548. https://dx.doi.org/10.1371/journal.pone.0169548Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One. 2017;12(1):e0169548. doi: https://dx.doi.org/10.1371/journal.pone.0169548Palacios S., Chedraui P., Sánchez-Borrego R., Coronado P., Nappi R.E. Obesity and menopause. Gynecol. Endocrinol. 2024; 40(1): 2312885. https://dx.doi.org/10.1080/09513590.2024.2312885Palacios S, Chedraui P, Sánchez-Borrego R, Coronado P, Nappi RE. Obesity and menopause. Gynecol. Endocrinol. 2024;40(1):2312885. doi: https://dx.doi.org/10.1080/09513590.2024.2312885O'Sullivan A.J., Crampton L.J., Freund J., Ho K.K. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 1998; 102(5): 1035-40. https://dx.doi.org/10.1172/JCI2773O’Sullivan AJ, Crampton LJ, Freund J, Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 1998;102(5):1035-40. doi: https://dx.doi.org/10.1172/JCI2773Mukherjee A., Ghaem-Maghami S., Syed A.A. Use of incretin-based therapies in women using hormone replacement therapy (HRT). Post Reprod. Health. 2025; 31(2): 127-31. https://dx.doi.org/10.1177/20533691251343069Mukherjee A, Ghaem-Maghami S, Syed AA. Use of incretin-based therapies in women using hormone replacement therapy (HRT). Post Reprod. Health. 2025;31(2):127-31. doi: https://dx.doi.org/10.1177/20533691251343069Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G.E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1): 230. https://dx.doi.org/10.1186/s12877-017-0621-2Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi: https://dx.doi.org/10.1186/s12877-017-0621-2Суджаева О.А. Проблема полипрагмазии при лечении сердечно-сосудистых заболеваний у лиц пожилого возраста: обзор Консенсуса экспертов рабочей группы Европейского общества кардиологов. Медицинские новости. 2022; 5: 20-6.Sujayeva V.A. The problem of polypharmacy in the treatment of cardiovascular diseases in the elderly: a review of the expert consensus of the working group of the European Society of Cardiology. Meditsinskie novosti. – 2022. – N5. – P. 20–26.Gosselin M., Talbot D., Simard M., Chiu Y.M., Mésidor M., Boiteau V. et al. Classifying polypharmacy according to pharmacotherapeutic and clinical risks in older adults: a latent class analysis in Quebec, Canada. Drugs Aging. 2023; 40(6): 573-83. https://dx.doi.org/10.1007/s40266-023-01028-2Gosselin M, Talbot D, Simard M, Chiu YM, Mésidor M, Boiteau V, et al. Classifying polypharmacy according to pharmacotherapeutic and clinical risks in older adults: a latent class analysis in Quebec, Canada. Drugs Aging. 2023;40(6):573-83. doi: https://dx.doi.org/10.1007/s40266-023-01028-2Юренева С.В. Менопаузальная гормональная терапия – индивидуализированный подход с позиции эффективности и безопасности: обзор международных рекомендаций. Акушерство и гинекология. 2024; 9: 36-46.Юренева С.В. Менопаузальная гормональная терапия – индивидуализированный подход с позиции эффективности и безопасности: обзор международных рекомендаций. // Акушерство и гинекология. — 2024. — № 9. — С. 36-46Rodriguez S., Gaunt T.R., Guo Y., Zheng J., Barnes M.R., Tang W. et al. Lipids, obesity and gallbladder disease in women: insights from genetic studies using the cardiovascular gene-centric 50K SNP array. Eur. J. Hum. Genet. 2016; 24(1): 106-12. https://dx.doi.org/10.1038/ejhg.2015.63Rodriguez S, Gaunt TR, Guo Y, Zheng J, Barnes MR, Tang W, et al. Lipids, obesity and gallbladder disease in women: insights from genetic studies using the cardiovascular gene-centric 50K SNP array. Eur. J. Hum. Genet. 2016;24(1):106-12. doi: https://dx.doi.org/10.1038/ejhg.2015.63Cirillo D.J. Effect of estrogen therapy on gallbladder disease. JAMA. 2005; 293: 330. https://dx.doi.org/10.1001/jama.293.3.330Cirillo D.J. Effect of estrogen therapy on gallbladder disease. JAMA. 2005;293:330. doi: https://dx.doi.org/10.1001/jama.293.3.330Liu B., Beral V., Balkwill A., Green J., Sweetland S., Reeves G.; Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008; 337: a386.Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G; Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008;337:a386. doi: doi: https://dx.doi.org/10.1136/bmj.a386https://dx.doi.org/10.1136/bmj.a386Saddique MN, Saleem S, Shahid I, Javid S, Hamza Khan M, Iqbal J. The estrogengallstone connection: uncovering the pathways. Discov. Public Health. 2024;21:113. doi: https://dx.doi.org/10.1186/s12982-024-00232-8Saddique MN, Saleem S, Shahid I, Javid S, Hamza Khan M, Iqbal J. The estrogengallstone connection: uncovering the pathways. Discov. Public Health. 2024;21:113. doi: https://dx.doi.org/10.1186/s12982-024-00232-8Saddique MN, Saleem S, Shahid I, Javid S, Hamza Khan M, Iqbal J. The estrogengallstone connection: uncovering the pathways. Discov. Public Health. 2024;21:113. doi: https://dx.doi.org/10.1186/s12982-024-00232-8Saddique M.N., Saleem S., Shahid I., Javid S., Hamza Khan M., Iqbal J. The estrogen gallstone connection: uncovering the pathways. Discov. Public Health. 2024; 21: 113. https://dx.doi.org/10.1186/s12982-024-00232-8Saddique M.N., Saleem S., Shahid I., Javid S., Hamza Khan M., Iqbal J. The estrogen gallstone connection: uncovering the pathways. Discov. Public Health. 2024; 21: 113. https://dx.doi.org/10.1186/s12982-024-00232-8

The authors declare that there are no conflicts of interest present.